Breaking News

WuXi Biologics Initiates Mfg. at Largest SU Biologics Facility

The 500,000 sq.-ft. facility quintuples existing manufacturing capability and will support biologics commercial manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics’ cGMP biologics manufacturing facility in Wuxi, with 30,000 L bioreactor capacity, began full operations, a significant milestone for the company as well as the biologics industry in China. In April 2015, WuXi Biologics invested $150 million to build the new biologics manufacturing facility and in September 2016, the first phase of construction was completed with two 1,000 L disposable bioreactors for perfusion processes. The second phase for the cGMP facility included an addit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters